Efficacy of Sleeping Without Pills (SWOP), an Online Drug Tapering Program

NCT ID: NCT03194802

Last Updated: 2018-03-14

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

72 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-06-05

Study Completion Date

2018-01-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aims of the study are to determine whether an online drug tapering program can lead to successful drug tapering in hypnotic dependent insomnia and whether such tapering is associated with improved daytime functioning and sleep.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Insomnia is defined as difficulty with falling asleep, staying asleep, or early morning awakening. Chronic insomnia is estimated to affect 9-15% of the world's population. Lack of sleep increases a person's risk for many chronic diseases such as obesity, diabetes, cardiovascular disease, anxiety and depression. The two types of treatment available for chronic insomnia are cognitive behavioural therapy (CBT) and pharmacotherapy, the latter of which includes benzodiazepines and non-benzodiazepines.

The use of hypnotic medications is intended to be prescribed as a short-term treatment of one or two weeks, however this is not the case most of the time. Hypnotic abuse and dependency are prevalent issues that increase with advancing age. With the regular intake of these substances comes many adverse effects such as sedation, cognitive and psychomotor effects, falls and other accidents. Relative to non-drug users, cognitive events are 5.0 times more likely, psychomotor events are 3.0 times more likely, and daytime fatigue is 4.0 times more likely among drug users. Both non-benzodiazepines and benzodiazepines have the potential for dependency and withdrawal, although zolpidem and other non-benzodiazepine hypnotic agents have become the preferred drugs to manage insomnia due to the lower side effect profile. Withdrawal symptoms are associated with a rapid dose decrease or abrupt discontinuance of medication. These symptoms include rebound insomnia, anxiety, memory and concentration impairments and in severe states, psychotic symptoms, delirium and epileptic seizures.

A recent comparison of cost data associated with pharmacotherapy and cognitive behavioral therapy showed that CBT was significantly less costly than pharmacotherapy. Unfortunately, CBT is often not applied due to limited access to appropriately trained practitioners. The combination of equivalent efficacy, reduced costs, and favorable side-effect profile have made cognitive behavioural therapy (CBT) the preferred treatment for insomnia as evidenced by endorsements with the American Academy of Sleep Medicine. More recently, the delivery of CBT for insomnia has been enhanced to be provided through web-based portals. A number of web-based programs for insomnia have been developed with promising results. Some of these programs measured hypnotic use.

The effect size associated with online CBT (without drug tapering component) on reducing hypnotic drug use has been small, and these studies have employed a mix of participants, only some of whom are interested in tapering with variable levels of motivation. Studies comparing CBT plus drug tapering with drug tapering alone using booklets and in-person sessions have found that such interventions are moderately effective in reducing dosage and frequency of sleep medication usage.

The aims of the study are to determine whether an online drug tapering program (Sleeping without Pills; SWOP) can lead to successful drug tapering in hypnotic dependent insomnia (primary aim), and whether such tapering is associated with improved daytime functioning and sleep (secondary aims).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Insomnia Chronic

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Sleeping Without Pills Program

Cognitive behavioral therapy; Motivational Interviewing; Scheduled and gradual drug tapering

Group Type EXPERIMENTAL

Sleeping Without Pills Program

Intervention Type BEHAVIORAL

Participants receive this program online and are asked to log in daily for 6 weeks.

Self-Monitoring

Daily Self-monitoring of sleep and sleep medication using sleep diary

Group Type ACTIVE_COMPARATOR

Self-monitoring

Intervention Type BEHAVIORAL

Participants enter sleep diary data online daily for 6 weeks

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Sleeping Without Pills Program

Participants receive this program online and are asked to log in daily for 6 weeks.

Intervention Type BEHAVIORAL

Self-monitoring

Participants enter sleep diary data online daily for 6 weeks

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

a) \>= 18 years, b) access to high speed internet and computer, c) disturbance of sleep consisting of a delay in sleep onset, return to sleep or early morning awakening at least 3 nights/week for at least 3 months in duration, d) at least one symptom of daytime impairment, use of medication to promote sleep, e) use of medication to promote sleep (either \<= 1mg lorazepam, \<= .5mg clonazepam, \<= 7.5mg zopiclone, \<= 50 mg trazodone/amitriptyline, f) interested in medication tapering.

Exclusion Criteria

a) shift work, b) head injury, c) acute crisis, d) seizure disorder, e) use of psychotropic drugs for problems other than sleep, f) use of medication interfering with sleep, g) recreational drug use, h) symptoms suggestive of alternative sleep disorder that is untreated, i) elevated use of alcohol (\> 14 beverages/week for males, \>12 beverages per week for females)
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Manitoba

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Dr. Nora Vincent

Clinical Psychologist

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Clinical Health Psychology

Winnipeg, Manitoba, Canada

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Canada

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

H2017:066

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Sodium Oxybate in Idiopathic Hypersomnia
NCT03597555 COMPLETED PHASE2/PHASE3
Insomnia and Drug Relapse Risk
NCT00253890 COMPLETED PHASE3
Sleep Well Observation Study
NCT05748574 COMPLETED NA